Frequency and Temporal Evolution of COVID-19 Vaccination Rate Among Oncological Patients Undergoing 18F-FDG-PET

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2022 Nov 13

PMID 36372666

Authors

Stephan Skawran

Helen Schiesser

Alexander Maurer

Thomas Sartoretti

Manuel Dittli

Cacilia Mader

Alessandra Curioni-Fontecedro

Christoph Berger

Martin W Huellner

Michael Messerli

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the temporal evolution of vaccination against COVID-19 in a Swiss oncological cohort.

Methods: History of complete vaccination (i.e. at least two vaccine doses) against COVID-19 of patients undergoing oncological 18F-FDG PET/CT between February and September 2021 (n = 2613) was taken. Vaccination rate was compared with age-matched national data from the Swiss Federal Office of Public Health. Subgroup differences in temporal evolution of vaccination rate were analyzed by fitting a generalized linear model and determined by significant interaction between, sex, oncological diagnosis, and month of examination.

Results: Rate of complete vaccination against COVID-19 steadily increased and reached 81 % in September 2021. The fraction of vaccinated patients in the oncological cohort was higher in the beginning and approached the fraction in the age-matched general Swiss population at the end of the study period. Month of exam (p < 0.001) was the only significant predictor of the vaccination rate.

Conclusion: Vaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021. Compared to the age-matched general population it was higher in the beginning and similar by the end of the study period. Ethics approval: Trial registration: BASEC 2021-00444, Ethikkommission Zürich (Cantonal Ethics Committee Zurich), Switzerland, registered February 24th 2021.

Citing Articles

Examination of iatrogenic FDG accumulation after COVID-19 vaccination.

Takahashi K, Manabe O, Shizukuishi K, Shibata H, Kawakami H, Otsuka A Ann Nucl Med. 2024; 38(6):409-417.

PMID: 38563890 DOI: 10.1007/s12149-024-01909-5.

References

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

Grivas P, Khaki A, Wise-Draper T, French B, Hennessy C, Hsu C . Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021; 32(6):787-800. PMC: 7972830. DOI: 10.1016/j.annonc.2021.02.024. View

Kuderer N, Choueiri T, Shah D, Shyr Y, Rubinstein S, Rivera D . Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395(10241):1907-1918. PMC: 7255743. DOI: 10.1016/S0140-6736(20)31187-9. View

Tsai R, Hervey J, Hoffman K, Wood J, Johnson J, Deighton D . COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey. JMIR Public Health Surveill. 2021; 8(1):e29872. PMC: 8734610. DOI: 10.2196/29872. View

Nguyen M, Bain N, Grech L, Choi T, Harris S, Chau H . COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study. Asia Pac J Clin Oncol. 2022; 18(6):570-577. DOI: 10.1111/ajco.13754. View

Moujaess E, Bou Zeid N, Samaha R, Sawan J, Kourie H, Labaki C . Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey. Future Oncol. 2021; 17(31):4071-4079. PMC: 8328088. DOI: 10.2217/fon-2021-0265. View

Bain N, Nguyen M, Grech L, Day D, McCartney A, Webber K . COVID-19 Vaccine Hesitancy in Australian Patients with Solid Organ Cancers. Vaccines (Basel). 2022; 10(9). PMC: 9503648. DOI: 10.3390/vaccines10091373. View

Peng X, Gao P, Wang Q, Wu H, Yan Y, Xia Y . Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China. Front Med (Lausanne). 2021; 8:741204. PMC: 8595240. DOI: 10.3389/fmed.2021.741204. View

Hess S, Blomberg B, Zhu H, Hoilund-Carlsen P, Alavi A . The pivotal role of FDG-PET/CT in modern medicine. Acad Radiol. 2014; 21(2):232-49. DOI: 10.1016/j.acra.2013.11.002. View

10.

Haas E, Angulo F, McLaughlin J, Anis E, Singer S, Khan F . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397(10287):1819-1829. PMC: 8099315. DOI: 10.1016/S0140-6736(21)00947-8. View

11.

Corti C, Curigliano G . Commentary: SARS-CoV-2 vaccines and cancer patients. Ann Oncol. 2021; 32(4):569-571. PMC: 7831848. DOI: 10.1016/j.annonc.2020.12.019. View